Results overview: Found 1 records in 0.02 seconds.
Articles, 1 records found
Articles 1 records found  
1.
19 p, 7.5 MB Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab / Granell-Geli, Júlia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Izquierdo-Gracia, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sellés-Rius, Ares (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Teniente Serra, Aina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Presas-Rodríguez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Mansilla Lopez, Maria Jose (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Brieva Ruiz, Luis (Hospital Universitari Arnau de Vilanova) ; Sotoca Fernández, Javier (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ; Mañé-Martínez, María Alba (Hospital Universitari Joan XXIII de Tarragona) ; Moral, Ester (Hospital de Sant Joan Despí Moisès Broggi) ; Bragado, Irene (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Goelz, Susan (Biogen Idec) ; Martínez Cáceres, Eva María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Natalizumab is a monoclonal antibody that binds CD49d. Although it is one of the most effective treatments for Relapsing-Remitting Multiple Sclerosis (RRMS), a dosing regimen has not been optimized for safety and efficacy in individual patients. [...]
2021 - 10.3390/jpm11121347
Journal of personalized medicine, Vol. 11 (december 2021)  

Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.